

# Alfredo Papa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4400252/publications.pdf>

Version: 2024-02-01

127  
papers

4,974  
citations

108046

37  
h-index

111975

67  
g-index

130  
all docs

130  
docs citations

130  
times ranked

6829  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intestinal Microbiome Modulation During Coronavirus Disease 2019: Another Chance to Manage the Disease?. <i>Gastroenterology</i> , 2022, 162, 2134.	0.6	5
2	CT and MRI Evaluations in Crohn's Complications: A Guide for the Radiologist. <i>Academic Radiology</i> , 2022, 29, 1206-1227.	1.3	16
3	Prognostic performance of the â€˜DICAâ€™™ endoscopic classification and the â€˜CODAâ€™™ score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study. <i>Gut</i> , 2022, 71, 1350-1358.	6.1	9
4	Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. <i>Biomedicines</i> , 2022, 10, 843.	1.4	6
5	Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211022.	1.4	7
6	A review of Magnetic Resonance Enterography classification and quantitative evaluation of active disease in patients with Crohn's disease. <i>Clinical Imaging</i> , 2021, 69, 50-62.	0.8	14
7	Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: The Picture Is Taking Shape. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 205-206.	2.4	0
8	How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists. <i>Vaccines</i> , 2021, 9, 248.	2.1	0
9	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 857-873.	8.2	56
10	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14755.	0.8	13
11	Development and Validation of Predictive Assessment of Complicated Diverticulitis Score. <i>Journal of Personalized Medicine</i> , 2021, 11, 80.	1.1	1
12	Orphan patients with inflammatory bowel disease - when we treat beyond evidence. <i>World Journal of Gastroenterology</i> , 2021, 27, 8047-8057.	1.4	1
13	Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 1722-1724.	0.2	21
14	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 902-903.	1.9	9
15	The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center. <i>Endoscopy International Open</i> , 2020, 08, E980-E984.	0.9	4
16	Assessment of neurological manifestations in hospitalized patients with COVID-19. <i>European Journal of Neurology</i> , 2020, 27, 2322-2328.	1.7	36
17	A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn's disease patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 857-865.	1.4	7
18	COVID-19 and intestinal inflammation: Role of fecal calprotectin. <i>Digestive and Liver Disease</i> , 2020, 52, 1231-1233.	0.4	40

#	ARTICLE	IF	CITATIONS
19	Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF- $\alpha$ treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1527-1532.	0.8	6
20	Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482096874.	1.4	4
21	Anti-TNF- $\alpha$ Agents in Inflammatory Bowel Disease and Course of COVID-19. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e73-e73.	0.9	25
22	SARS-CoV2 RNA detection in a pancreatic pseudocyst sample. <i>Pancreatology</i> , 2020, 20, 1011-1012.	0.5	59
23	Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: a case report and review of the literature. <i>BMC Gastroenterology</i> , 2020, 20, 76.	0.8	11
24	Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery. <i>Journal of Clinical Medicine</i> , 2020, 9, 2115.	1.0	10
25	COVID-19 infection in Crohn's disease under treatment with adalimumab. <i>Gut</i> , 2020, 69, 1364-1365.	6.1	46
26	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020, 71, 689-697.	0.8	19
27	Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. <i>United European Gastroenterology Journal</i> , 2020, 8, 775-781.	1.6	40
28	Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center. <i>Nutrients</i> , 2019, 11, 2281.	1.7	47
29	Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 1189-1197.	1.6	31
30	Assessment of Crohn's Disease Activity: Magnetic Resonance Enterography in Comparison with Clinical and Endoscopic Evaluations. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 213-224.	0.5	6
31	Hot Topics in Surgical Management of Acute Diverticulitis. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 29-34.	0.5	2
32	International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 57-66.	0.5	21
33	The "DICA" Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 23-27.	0.5	6
34	The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 39-44.	0.5	2
35	Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)- $\alpha$ on the Liver. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2199.	1.8	62
36	Biologic therapies in ulcerative colitis: primi inter pares?. <i>Current Drug Targets</i> , 2018, 19, 748-756.	1.0	3

#	ARTICLE	IF	CITATIONS
37	Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells. <i>American Journal of Pathology</i> , 2017, 187, 1633-1647.	1.9	42
38	Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. <i>Digestion</i> , 2017, 96, 166-172.	1.2	15
39	Anti TNF- $\alpha$ therapy for ulcerative colitis: current status and prospects for the future. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 223-233.	1.3	78
40	Can We Predict the Efficacy of Anti-TNF- $\alpha$ Agents?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1973.	1.8	73
41	Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. <i>PLoS ONE</i> , 2017, 12, e0186575.	1.1	23
42	Benefit&ndash;risk assessment of golimumab in the treatment of refractory ulcerative colitis. <i>Drug, Healthcare and Patient Safety</i> , 2016, 8, 1.	1.0	3
43	Role and mechanisms of action of <i>Escherichia coli</i> Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. <i>World Journal of Gastroenterology</i> , 2016, 22, 5505.	1.4	141
44	Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease. <i>Digestive Diseases</i> , 2016, 34, 202-209.	0.8	18
45	Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis. <i>Transplantation Proceedings</i> , 2016, 48, 402-407.	0.3	26
46	Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jcw181.	0.6	27
47	The Economic Burden of Diverticular Disease. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, S2-S3.	1.1	19
48	Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study. <i>United European Gastroenterology Journal</i> , 2016, 4, 604-613.	1.6	33
49	Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action. <i>Digestive and Liver Disease</i> , 2016, 48, 391-398.	0.4	17
50	Infliximab does not increase colonic cancer risk associated to murine chronic colitis. <i>World Journal of Gastroenterology</i> , 2016, 22, 9727.	1.4	5
51	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 387.	0.6	6
52	Prevention and Treatment of Venous Thromboembolism in Patients with IBD. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1204-1213.	0.9	28
53	Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 664-684.	1.9	102
54	Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 880-888.	1.9	94

#	ARTICLE	IF	CITATIONS
55	Therapeutic drug monitoring of anti-TNF- $\hat{\pm}$ agents in inflammatory bowel diseases. Expert Opinion on Biological Therapy, 2015, 15, 1107-1117.	1.4	13
56	Venous thromboembolism in patients with inflammatory bowel disease: Focus on prevention and treatment. World Journal of Gastroenterology, 2014, 20, 3173.	1.4	63
57	Anti-TNF- $\hat{\pm}$ -induced psoriasiform lesions in IBD: an abnormal immune activation or a "patchy cutaneous" immune suppression?. Gut, 2014, 63, 699-701.	6.1	4
58	Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis. Inflammatory Bowel Diseases, 2014, 20, 1368-1374.	0.9	55
59	342 Retreatment With Infliximab in Inflammatory Bowel Disease: Tolerability and Effectiveness of Different Re-Induction Regimens. Gastroenterology, 2014, 146, S-78-S-79.	0.6	1
60	Inter-observer agreement in endoscopic scoring systems: Preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2014, 46, 969-973.	0.4	78
61	Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor $\hat{\pm}$ agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. Digestive and Liver Disease, 2014, 46, 974-979.	0.4	64
62	Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. Digestive and Liver Disease, 2014, 46, 290-291.	0.4	1
63	Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: An open-label pilot study. Journal of Crohn's and Colitis, 2013, 7, e623-e629.	0.6	85
64	Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, 769-779.	0.6	114
65	Locally injected Infliximab ameliorates murine DSS colitis: Differences in serum and intestinal levels of drug between healthy and colitic mice. Digestive and Liver Disease, 2013, 45, 1017-1021.	0.4	38
66	Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor- $\hat{\pm}$ agents. Journal of Crohn's and Colitis, 2013, 7, 113-119.	0.6	68
67	A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: Infliximab and surgery. Journal of Crohn's and Colitis, 2013, 7, 421-426.	0.6	18
68	Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF- $\hat{\pm}$ agents: Effects of combined therapy with immunosuppressants. Journal of Crohn's and Colitis, 2013, 7, 301-307.	0.6	86
69	FOXP3 <sup>+</sup> Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF Agents. BioMed Research International, 2013, 2013, 1-10.	0.9	31
70	Infliximab in Steroid-dependent Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 1065-1072.	0.9	66
71	Mucosal healing in ulcerative colitis: surveillance or colectomy?. Annals of Gastroenterology, 2013, 26, 355.	0.4	1
72	Ileal Crohn Disease: Mural Microvasculature Quantified with Contrast-enhanced US Correlates with Disease Activity. Radiology, 2012, 262, 680-688.	3.6	74

#	ARTICLE	IF	CITATIONS
73	Exacerbation of Crohn's disease as paradoxical effect of infliximab. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 396.	0.6	2
74	Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. <i>International Journal of Colorectal Disease</i> , 2011, 26, 1435-1444.	1.0	66
75	Onset of severe perianal disease in Crohn's disease under treatment with infliximab. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 676-678.	0.9	3
76	Response to Jackson et al.. <i>American Journal of Gastroenterology</i> , 2011, 106, 547-548.	0.2	1
77	Clinical trial: oral colon-release parnaparin sodium tablets (CB-015 MMX <sup>®</sup> ) for active left-sided ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 375-386.	1.9	29
78	Response to Mahadevan and Kane. <i>American Journal of Gastroenterology</i> , 2010, 105, 219-220.	0.2	1
79	A Case of Hereditary Hemorrhagic Telangiectasia Associated With Crohn's Disease Successfully Treated With Infliximab. <i>American Journal of Gastroenterology</i> , 2010, 105, 1904.	0.2	4
80	Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study. <i>American Journal of Gastroenterology</i> , 2010, 105, 2218-2227.	0.2	390
81	Biological therapies for inflammatory bowel disease: controversies and future options. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 391-403.	1.3	18
82	Response to El-Matary. <i>American Journal of Gastroenterology</i> , 2009, 104, 2852-2853.	0.2	0
83	Use of Infliximab in Particular Clinical Settings: Management Based on Current Evidence. <i>American Journal of Gastroenterology</i> , 2009, 104, 1575-1586.	0.2	37
84	Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. <i>Techniques in Coloproctology</i> , 2008, 12, 111-117.	0.8	38
85	Intima-Media Thickness in Inflammatory Bowel Disease Patients: A Still Open Question. <i>American Journal of Gastroenterology</i> , 2008, 103, 490-490.	0.2	2
86	Vascular Involvement in Inflammatory Bowel Disease: Pathogenesis and Clinical Aspects. <i>Digestive Diseases</i> , 2008, 26, 149-155.	0.8	60
87	PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 826-828.	0.8	13
88	Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens. <i>American Journal of Gastroenterology</i> , 2007, 102, 174-186.	0.2	322
89	Biological Therapies For Inflammatory Bowel Disease: Research Drives Clinics. <i>Mini-Reviews in Medicinal Chemistry</i> , 2006, 6, 771-784.	1.1	32
90	Increased carotid intima-media thickness in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 839-846.	1.9	97

#	ARTICLE	IF	CITATIONS
91	Extraintestinal manifestations in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2005, 11, 7227.	1.4	358
92	Homocysteine Triggers Mucosal Microvascular Activation in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 886-895.	0.2	119
93	Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation. <i>Digestive and Liver Disease</i> , 2005, 37, 811-818.	0.4	88
94	CD40L-Positive Platelets Induce CD40L Expression De Novo in Endothelial Cells: Adding a Loop to Microvascular Inflammation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, e162.	1.1	17
95	<i>Helicobacter pylori</i> eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer. <i>Gastroenterology</i> , 2004, 126, 369-371.	0.6	10
96	Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2004, 36, 528-532.	0.4	14
97	Primary hyperparathyroidism: acute paranoid psychosis. <i>American Journal of Emergency Medicine</i> , 2003, 21, 250-251.	0.7	17
98	Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. <i>Gut</i> , 2003, 52, 1435-1441.	6.1	223
99	To perform or not to perform liver biopsy: an alternative view. <i>Gut</i> , 2003, 52, 1227-1227.	6.1	0
100	Review Article: Inherited Thrombophilia in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2003, 98, 1247-1251.	0.2	95
101	Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events. <i>Hepato-Gastroenterology</i> , 2003, 50, 132-5.	0.5	7
102	Genetic and nutritional predictors of hyperhomocysteinemia in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2002, 97, 490-491.	0.2	5
103	Role of <i>Helicobacter pylori</i> CagA + Infection in Determining Oxidative DNA Damage in Gastric Mucosa. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 409-413.	0.6	41
104	When can unfractionated heparin really be useful in the treatment of ulcerative colitis?. <i>Gastroenterology</i> , 2001, 120, 1306-1307.	0.6	4
105	Thrombotic Complications in Inflammatory Bowel Disease: A Multifactorial Etiology. <i>American Journal of Gastroenterology</i> , 2001, 96, 1301-1302.	0.2	4
106	<i>Helicobacter pylori</i> CagA-positive Strains Affect Oxygen Free Radicals Generation by Gastric Mucosa. <i>Scandinavian Journal of Gastroenterology</i> , 2001, 36, 247-250.	0.6	45
107	Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 2677-2682.	0.2	88
108	Is Cytotoxic-associated Gene A-positive <i>Helicobacter pylori</i> Important?. <i>Journal of Clinical Gastroenterology</i> , 2001, 32, 91-92.	1.1	1

#	ARTICLE	IF	CITATIONS
109	Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. <i>Blood Coagulation and Fibrinolysis</i> , 2000, 11, 499-503.	0.5	33
110	<i>Helicobacter pylori</i> Eradication and Remission of Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma. <i>Journal of Clinical Gastroenterology</i> , 2000, 31, 169-171.	1.1	36
111	Potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1403-1409.	1.9	68
112	Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against <i>Helicobacter pylori</i> infection. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2386-2389.	1.1	6
113	Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure <i>Helicobacter pylori</i> infection. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 247-250.	0.8	15
114	One-week therapy for <i>Helicobacter pylori</i> eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxicillin. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 539-543.	1.9	13
115	Variation of the endoscopic pattern of low-grade gastric malt-lymphoma after <i>Helicobacter pylori</i> eradication. <i>Gastrointestinal Endoscopy</i> , 1998, 48, 231-232.	0.5	5
116	Disappearance of Gastric Mucosa-Associated Lymphoid Tissue in Coeliac Patients after Gluten Withdrawal. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 401-405.	0.6	25
117	What is the best azithromycin-based therapy for <i>Helicobacter pylori</i> infection?. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 39, 111-111.	1.3	1
118	Endoscopic findings and clinical patterns are not useful for distinguishing low from high grade gastric MALT lymphoma. Reply. <i>Gut</i> , 1997, 41, 577-577.	6.1	3
119	Gastric Mucosa-Associated Lymphoid Tissue in Autoimmune Thyroid Diseases. <i>Scandinavian Journal of Gastroenterology</i> , 1997, 32, 869-872.	0.6	27
120	The Growth of Primary Low-Grade B-Cell Gastric Lymphoma Is Sustained by <i>Helicobacter pylori</i> . <i>Scandinavian Journal of Gastroenterology</i> , 1997, 32, 285-287.	0.6	27
121	Editorial: The Role of Endoscopy in the Diagnosis and Follow-up of Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Journal of Clinical Gastroenterology</i> , 1997, 25, 496-498.	1.1	5
122	Eradication of <i>Helicobacter pylori</i> as the first step in the treatment of peptic stenosis. <i>Gastrointestinal Endoscopy</i> , 1996, 44, 757.	0.5	1
123	<i>Helicobacter pylori</i> eradication using one-week low-dose lansoprazole plus amoxicillin and either clarithromycin or azithromycin. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 997-1000.	1.9	32
124	Low-dose omeprazole plus clarithromycin and either tinidazole or amoxicillin for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 285-288.	1.9	27
125	Role of Dental Plaque in the Transmission of <i>Helicobacter Pylori</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 1996, 22, 174-177.	1.1	65
126	<i>Helicobacter Pylori</i> Eradication Helps Resolve Pyloric and Duodenal Stenosis. <i>Journal of Clinical Gastroenterology</i> , 1996, 23, 157-158.	1.1	26

#	ARTICLE	IF	CITATIONS
127	Prevention and Treatment of Low-grade B-cell Primary Gastric Lymphoma by Anti-H. Pylori Therapy. Journal of Clinical Gastroenterology, 1995, 21, 118-122.	1.1	53